home / stock / okyo / okyo news

OKYO News and Press, OKYO Pharma Limited From 02/28/23

Stock Information
Company Name: OKYO Pharma Limited
Stock Symbol: OKYO
Market: NASDAQ
Website: okyopharma.com
Menu
OKYO OKYO Quote OKYO Short OKYO News OKYO Articles OKYO Message Board
Get OKYO Alerts

News, Short Squeeze, Breakout and More Instantly...
OKYO - Okyo stock pops as eye drug package gets customs clearance to enter US

London-based Okyo Pharma ( NASDAQ: OKYO ) it received customs clearance in the U.S. for its GMP packaged OK-101 drug, shipped from Europe, to be used in an upcoming phase 2 trial in patients with dry eye disease (DED). Okyo expects the first-patient-first visit in Q1 2023 an...
OKYO - OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease

LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today anno...

OKYO - Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution

(NewsDirect) By David Willey, Benzinga An eye condition that has been described as a common disease currently affects as many as 49 million Americans . Dry Eye Disease (DED) afflicts over 15% of Americans over 50 and disproportionately affects women and DED patients are not well s...

OKYO - Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective - OKYO Pharma's Drug Candidate Could Be The Solution

--News Direct-- By David Willey, Benzinga An eye condition that has been described as a common disease currently affects as many as 49 million Americans . Dry Eye Disease (DED) afflicts over 15% of Americans over 50 and disproportionately affects women and DED patients are not wel...
OKYO - OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board

LONDON and NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces the...

OKYO - BABA Stock Alert: What to Know as Ant Group Teams Up With China's NBA League

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Alex Kravtsov / Shutterstock.com Alibaba (NYSE: BABA ) stock is a hot topic on Tuesday as investors react to news of Ant Group teaming up with China’s NBA league . With this news, Ant Group, a fi...

OKYO - Why Is OKYO Pharma (OKYO) Stock Down 19% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock OKYO Pharma  (NASDAQ: OKYO ) stock is falling on Tuesday as the company prepares for a presentation this week . OKYO Pharma is attending the 2nd Annual GPCRs-Targeted Drug Discovery Summi...
OKYO - OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.

LONDON and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) (“OKYO”, “OKYO Pharma” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to addre...

OKYO - OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its...

OKYO - Okyo stock rises 10% on FDA nod to start trial of dry eye disease therapy

The U.S. Food and Drug Administration (FDA) cleared Okyo Pharma's ( NASDAQ: OKYO ) investigational new drug (IND) to start a phase 2 trial of OK-101 for treating dry eye disease (DED). The London-based company said that the FDA previously agreed with its plans for designating...
Previous 10 Next 10